Literature DB >> 6705451

Kinetics of the epimeric glucocorticoid budesonide.

A Ryrfeldt, S Edsbäcker, R Pauwels.   

Abstract

Budesonide is a potent nonhalogenated glucocorticoid consisting of a 1/1 mixture of the two epimers 22R and 22S. The kinetics of these epimers were studied in six healthy male subjects after intravenous administration of 500 micrograms 3H-budesonide. Estimation of the epimer concentrations in plasma was made possible by development of an HPLC method for simultaneous separation and quantification. The plasma t 1/2, distribution volume (V beta), and plasma clearance for epimer 22R were (mean +/- SD) 2.66 +/- 0.57 hr, 425 +/- 100 l, and 117 +/- 40 l/hr. The corresponding values for epimer 22S were 2.71 +/- 0.69 hr, 245 +/- 38 l, and 67 +/- 19 l/hr. Differences in V beta and plasma clearance between the two were significant. The larger V beta noted for epimer 22R may be a result of higher tissue affinity. The high plasma clearance for both epimers should largely reflect their high rate of liver biotransformation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6705451     DOI: 10.1038/clpt.1984.71

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung.

Authors:  C Minto; B Li; B Tattam; K Brown; J P Seale; R Donnelly
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 3.  Budesonide for the treatment of ulcerative colitis.

Authors:  Maisa I Abdalla; Hans Herfarth
Journal:  Expert Opin Pharmacother       Date:  2016-06-16       Impact factor: 3.889

Review 4.  Clinical pharmacokinetics of inhaled budesonide.

Authors:  R Donnelly; J P Seale
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 6.  [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].

Authors:  U Klotz
Journal:  Med Klin (Munich)       Date:  1999-02-15

7.  An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers.

Authors:  Anna Lönnebo; Anders Grahnén; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2007-03-01       Impact factor: 4.335

Review 8.  Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders.

Authors:  K M Hvizdos; B Jarvis
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 9.  Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.

Authors:  Staffan Edsbäcker; Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Pharmacokinetics of budesonide in children with asthma.

Authors:  S Pedersen; G Steffensen; I Ekman; M Tönnesson; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.